{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Fièvre chikungunya : Questions médicales les plus fréquentes",
"headline": "Fièvre chikungunya : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Fièvre chikungunya : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-09",
"dateModified": "2025-04-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Fièvre chikungunya"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Infections à alphavirus",
"url": "https://questionsmedicales.fr/mesh/D018354",
"about": {
"@type": "MedicalCondition",
"name": "Infections à alphavirus",
"code": {
"@type": "MedicalCode",
"code": "D018354",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.925.782.930.100"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Fièvre chikungunya",
"alternateName": "Chikungunya Fever",
"code": {
"@type": "MedicalCode",
"code": "D065632",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Angela Luzia Branco Pinto Duarte",
"url": "https://questionsmedicales.fr/author/Angela%20Luzia%20Branco%20Pinto%20Duarte",
"affiliation": {
"@type": "Organization",
"name": "Departamento de Medicina Clínica, Universidade Federal de Pernambuco, Recife, PE, Brasil."
}
},
{
"@type": "Person",
"name": "Claudia Diniz Lopes Marques",
"url": "https://questionsmedicales.fr/author/Claudia%20Diniz%20Lopes%20Marques",
"affiliation": {
"@type": "Organization",
"name": "Serviço de Reumatologia - Hospital das Clínicas da Universidade Federal de Pernambuco, Núcleo de Pesquisa em Inovação Terapêutica Suely Galdino (Nupit-SG)/ UFPE, Endereço: Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife, PE, CEP: 50670-901, Brazil."
}
},
{
"@type": "Person",
"name": "Scott C Weaver",
"url": "https://questionsmedicales.fr/author/Scott%20C%20Weaver",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Nara Gualberto Cavalcanti",
"url": "https://questionsmedicales.fr/author/Nara%20Gualberto%20Cavalcanti",
"affiliation": {
"@type": "Organization",
"name": "Serviço de Reumatologia - Hospital das Clínicas da Universidade Federal de Pernambuco, Núcleo de Pesquisa em Inovação Terapêutica Suely Galdino (Nupit-SG)/ UFPE, Endereço: Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife, PE, CEP: 50670-901, Brazil. Electronic address: nara.gual@gmail.com."
}
},
{
"@type": "Person",
"name": "Moacyr Jesus Barreto de Melo Rêgo",
"url": "https://questionsmedicales.fr/author/Moacyr%20Jesus%20Barreto%20de%20Melo%20R%C3%AAgo",
"affiliation": {
"@type": "Organization",
"name": "Serviço de Reumatologia - Hospital das Clínicas da Universidade Federal de Pernambuco, Núcleo de Pesquisa em Inovação Terapêutica Suely Galdino (Nupit-SG)/ UFPE, Endereço: Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife, PE, CEP: 50670-901, Brazil."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cellular and Molecular Diversity in Scleroderma.",
"datePublished": "2022-08-06",
"url": "https://questionsmedicales.fr/article/35940960",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.smim.2022.101648"
}
},
{
"@type": "ScholarlyArticle",
"name": "Spatial Transcriptomics Identifies Cellular and Molecular Characteristics of Scleroderma Skin Lesions: Pilot Study in Juvenile Scleroderma.",
"datePublished": "2024-08-23",
"url": "https://questionsmedicales.fr/article/39273131",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms25179182"
}
},
{
"@type": "ScholarlyArticle",
"name": "Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-Centered Intervention Network Cohort Study.",
"datePublished": "2022-05-11",
"url": "https://questionsmedicales.fr/article/33527717",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/acr.24567"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pulmonary Hypertension in Scleroderma- Evaluation and Management.",
"datePublished": "2022-09-24",
"url": "https://questionsmedicales.fr/article/36163292",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.disamonth.2022.101468"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.",
"datePublished": "2022-10-14",
"url": "https://questionsmedicales.fr/article/36244404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.chest.2022.09.044"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Infection",
"item": "https://questionsmedicales.fr/mesh/D007239"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies virales",
"item": "https://questionsmedicales.fr/mesh/D014777"
},
{
"@type": "ListItem",
"position": 4,
"name": "Infections à virus à ARN",
"item": "https://questionsmedicales.fr/mesh/D012327"
},
{
"@type": "ListItem",
"position": 5,
"name": "Infections à Togaviridae",
"item": "https://questionsmedicales.fr/mesh/D014036"
},
{
"@type": "ListItem",
"position": 6,
"name": "Infections à alphavirus",
"item": "https://questionsmedicales.fr/mesh/D018354"
},
{
"@type": "ListItem",
"position": 7,
"name": "Fièvre chikungunya",
"item": "https://questionsmedicales.fr/mesh/D065632"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Fièvre chikungunya - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Fièvre chikungunya",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Fièvre chikungunya",
"description": "Comment diagnostiquer la fièvre chikungunya ?\nQuels tests sont utilisés pour confirmer l'infection ?\nQuels symptômes indiquent une infection ?\nLa fièvre chikungunya est-elle confondue avec d'autres maladies ?\nQuel est le délai d'apparition des symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D065632?mesh_terms=Scleroderma,+Systemic&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Fièvre chikungunya",
"description": "Quels sont les symptômes principaux de la fièvre chikungunya ?\nLa douleur articulaire est-elle persistante ?\nY a-t-il des symptômes gastro-intestinaux ?\nLes symptômes varient-ils selon l'âge ?\nPeut-on avoir des symptômes sans fièvre ?",
"url": "https://questionsmedicales.fr/mesh/D065632?mesh_terms=Scleroderma,+Systemic&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Fièvre chikungunya",
"description": "Comment prévenir la fièvre chikungunya ?\nLes moustiquaires sont-elles efficaces ?\nFaut-il éliminer les eaux stagnantes ?\nLes vaccins existent-ils pour cette maladie ?\nComment se protéger lors de voyages ?",
"url": "https://questionsmedicales.fr/mesh/D065632?mesh_terms=Scleroderma,+Systemic&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Fièvre chikungunya",
"description": "Quel est le traitement recommandé pour la fièvre chikungunya ?\nLes anti-inflammatoires sont-ils efficaces ?\nFaut-il se reposer pendant la maladie ?\nDes remèdes naturels sont-ils utiles ?\nQuand consulter un médecin ?",
"url": "https://questionsmedicales.fr/mesh/D065632?mesh_terms=Scleroderma,+Systemic&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Fièvre chikungunya",
"description": "Quelles sont les complications possibles de la fièvre chikungunya ?\nLa fièvre chikungunya peut-elle être mortelle ?\nLes personnes âgées sont-elles plus à risque ?\nY a-t-il des risques de co-infection ?\nComment gérer les douleurs chroniques post-chikungunya ?",
"url": "https://questionsmedicales.fr/mesh/D065632?mesh_terms=Scleroderma,+Systemic&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Fièvre chikungunya",
"description": "Qui est le plus à risque de contracter la maladie ?\nLes femmes enceintes sont-elles plus vulnérables ?\nLes personnes immunodéprimées sont-elles à risque ?\nLes enfants sont-ils plus touchés ?\nLes voyages dans des zones endémiques augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D065632?mesh_terms=Scleroderma,+Systemic&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la fièvre chikungunya ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur les symptômes cliniques et des tests sérologiques ou PCR."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer l'infection ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests sérologiques détectent les anticorps, tandis que la PCR identifie le virus."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une infection ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, douleurs articulaires, éruptions cutanées et fatigue sont des indicateurs clés."
}
},
{
"@type": "Question",
"name": "La fièvre chikungunya est-elle confondue avec d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec la dengue ou le virus Zika en raison de symptômes similaires."
}
},
{
"@type": "Question",
"name": "Quel est le délai d'apparition des symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes apparaissent généralement 4 à 8 jours après la piqûre d'un moustique infecté."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux de la fièvre chikungunya ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fièvre, douleurs articulaires, maux de tête et éruptions cutanées."
}
},
{
"@type": "Question",
"name": "La douleur articulaire est-elle persistante ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la douleur articulaire peut persister plusieurs mois après la guérison initiale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes gastro-intestinaux ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des nausées ou des vomissements peuvent survenir, mais sont moins fréquents."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les enfants et les personnes âgées peuvent présenter des symptômes plus sévères et prolongés."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans fièvre ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent éprouver des douleurs articulaires sans fièvre initiale."
}
},
{
"@type": "Question",
"name": "Comment prévenir la fièvre chikungunya ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les piqûres de moustiques en utilisant des répulsifs et en portant des vêtements longs."
}
},
{
"@type": "Question",
"name": "Les moustiquaires sont-elles efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les moustiquaires traitées avec insecticide protègent contre les piqûres de moustiques."
}
},
{
"@type": "Question",
"name": "Faut-il éliminer les eaux stagnantes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éliminer les eaux stagnantes réduit les lieux de reproduction des moustiques."
}
},
{
"@type": "Question",
"name": "Les vaccins existent-ils pour cette maladie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin approuvé contre la fièvre chikungunya."
}
},
{
"@type": "Question",
"name": "Comment se protéger lors de voyages ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utilisez des répulsifs, portez des vêtements longs et choisissez des hébergements protégés."
}
},
{
"@type": "Question",
"name": "Quel est le traitement recommandé pour la fièvre chikungunya ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement antiviral spécifique; les soins sont symptomatiques."
}
},
{
"@type": "Question",
"name": "Les anti-inflammatoires sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anti-inflammatoires non stéroïdiens peuvent soulager la douleur et l'inflammation."
}
},
{
"@type": "Question",
"name": "Faut-il se reposer pendant la maladie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un repos adéquat est conseillé pour aider à la récupération et réduire la fatigue."
}
},
{
"@type": "Question",
"name": "Des remèdes naturels sont-ils utiles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains remèdes naturels peuvent aider à soulager les symptômes, mais peu de preuves existent."
}
},
{
"@type": "Question",
"name": "Quand consulter un médecin ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez un médecin si les symptômes s'aggravent ou si des complications apparaissent."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la fièvre chikungunya ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des douleurs articulaires chroniques et des problèmes neurologiques."
}
},
{
"@type": "Question",
"name": "La fièvre chikungunya peut-elle être mortelle ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fièvre chikungunya n'est généralement pas mortelle, mais des complications peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent développer des complications plus graves et prolongées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de co-infection ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la co-infection avec d'autres virus comme la dengue peut compliquer le tableau clinique."
}
},
{
"@type": "Question",
"name": "Comment gérer les douleurs chroniques post-chikungunya ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut des traitements anti-inflammatoires et des thérapies physiques."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque de contracter la maladie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes vivant dans des zones endémiques et celles exposées aux moustiques sont à risque."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes sont-elles plus vulnérables ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes enceintes peuvent avoir des complications plus graves et affecter le fœtus."
}
},
{
"@type": "Question",
"name": "Les personnes immunodéprimées sont-elles à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées peuvent développer des formes plus sévères de la maladie."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus touchés ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les enfants peuvent contracter la maladie, mais les symptômes sont souvent moins sévères."
}
},
{
"@type": "Question",
"name": "Les voyages dans des zones endémiques augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones où le chikungunya est présent augmente le risque d'infection."
}
}
]
}
]
}
With the increasing armamentarium of high-throughput tools available at manageable cost, it is attractive and informative to determine the molecular underpinnings of patient heterogeneity in systemic ...
Juvenile localized and systemic scleroderma are rare autoimmune diseases which cause significant disability and morbidity in children. The mechanisms driving juvenile scleroderma remain unclear, neces...
To support physical activity among people with systemic sclerosis (SSc [scleroderma]), we sought to determine the prevalence and importance of barriers and the likelihood of using possible facilitator...
We invited 1,707 participants from an international SSc cohort to rate the importance of 20 barriers (14 medical, 4 social or personal, 1 lifestyle, and 1 environmental) and the likelihood of using 91...
Among 721 respondents, 13 barriers were experienced by ≥25% of participants, including 2 barriers (fatigue and Raynaud's phenomenon) rated "important" or "very important" by ≥50% of participants, 7 ba...
Medical-related physical activity barriers were common and considered important. Facilitators considered as most likely to be used involved adapting exercise, taking care of one's body, keeping warm, ...
Pulmonary Arterial Hypertension (PAH) is a clinical syndrome consisting of physiologic/hemodynamic criteria that are a consequence of several etiologies. Systemic Sclerosis (SSc), one of the most comm...
Enrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have not been tested in a real-life cohort....
Do enrichment strategies for progressive ILD impact efficacy, representativeness, and feasibility in patients with SSc-ILD from the European Scleroderma Trials and Research (EUSTAR) database?...
We applied the inclusion criteria of major recent SSc-ILD trials (Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis [focuSSced], Scleroderma Lung Study II [SLS II...
In total, 2,258 patients with SSc-ILD were included: 31.2% of the patients met SENSCIS criteria; 5.8% of the patients met SLS II criteria; 1.6% of the patients met focuSSced criteria, and 67.7% (1,529...
The application of enrichment criteria from previous clinical trials showed enrichment for progression with variable success, which led to selected patient populations reducing feasibility of recruitm...
Patients with systemic sclerosis (SSc) are at increased risk of cancer, a growing cause of non-SSc-related death among these patients. We analyzed the increased cancer risk among Spanish patients with...
Spanish Scleroderma Registry data were analyzed to determine the demographic characteristics of patients with SSc, and logistic regression was used to identify cancer risk factors. SIRs with 95% confi...
Of 1930 patients with SSc, 206 had cancer, most commonly breast, lung, hematological, and colorectal cancers. Patients with SSc had increased risks of overall cancer (SIR 1.48, 95% CI 1.36-1.60; P < 0...
Spanish patients with SSc had an increased cancer risk compared with the general population. Some characteristics, including specific autoantibodies, may be related to this increased risk....
One of the key clinical challenges of systemic sclerosis (SSc) is diversity in clinical presentation, organ involvement and disease progression. Antinuclear autoantibodies (ANA) are central to the dia...
There has been further development in delineating clinical patterns in ANA, genetic susceptibility and antigen triggers predisposing to ANA subtypes. Sub-group analysis of recent clinical trials shows...
ANA subtyping is likely to be firmly embedded into future classification systems. Beyond informing current management and monitoring of scleroderma patients, ANA subsets have implication on future res...
The mechanisms of systemic autoimmune diseases (ADs) are still not clearly understood. Understanding the etiology of systemic ADs and identifying new therapeutic targets require a systems science appr...
People with systemic sclerosis (SSc) are vulnerable in COVID-19 and face challenges related to shifting COVID-19 risk and protective restrictions. We evaluated mental health symptom trajectories in pe...
The longitudinal Scleroderma Patient-centred Intervention Network (SPIN) COVID-19 cohort was launched in April 2020 and included participants from the ongoing SPIN Cohort and external enrolees. Analys...
Anxiety symptoms increased in early 2020 but returned to pre-COVID-19 levels by mid-2020 and remained stable through March 2022. Depression symptoms did not initially change but were slightly lower by...
People with SSc continue to face COVID-19 challenges related to ongoing risk, the opening of societies, and removal of protective restrictions. People with SSc, in aggregate, appear to be weathering t...
Systemic sclerosis (SSc) is a rare auto-immune disease, affecting principally women between 40 and 60 years old. It is caracterised by a cutaneous and visceral fibrosis, an alteration of the microvasc...
We have analysed the data of a retrospective and bicentrique cohort, from the internal medicine unit of Hôpital Nord in Marseille and from the internal medicine unit of the Hôpital Sainte-Anne in Toul...
The cohort included 151 patients including 134 limited cutaneous SSc. Fifty-two (34.4%) patients presented at least one associated auto-immune or inflammatory disease. The association of two connectiv...
SSc is often associated with other autoimmune diseases. This interrelation between associated pathologies and SSc, modifying sometimes the evolution of SSc, enhances the need of a personalized follow-...